CARY — UV Innovators, an ultraviolet technology company, has launched NuvaWave, billed as an advanced tool in the fight against deadly pathogens, including the novel coronavirus.
NuvaWave is a UVC handheld device used to disinfect any high-touch surface. This product release is timely as all businesses, schools, municipalities, airlines, cruise ships and other commercial ventures need a solution to protect their employees, students, customers and family from COVID-19, said Dr. Nicholas Medendorp Jr., CEO of UV Innovators, a company that touts two decades of LED experience and holder of 115 patents.
“In order for people to feel comfortable getting back to normal, they must feel confident that the places they go are clean and free from infectious pathogens,” Medendorp said.
Dr. David J. Weber recently joined the scientific advisory board of UV Innovators. Since the first days of the coronavirus outbreak, Weber has worked with the Centers for Disease Control and Prevention, Food and Drug Administration and other health agencies to understand the coronavirus and its mechanism for community spread, according to information from UV Innovators.
“The global public health and financial impact of COVID-19 have put a strain on resources and created a substantial need to find therapeutic and preventative solutions quickly,” Weber said. “People are coming to understand the necessity of social distancing, wearing a face mask, having good hand hygiene and effective surface disinfection solutions.”
Weber serves as professor of medicine and pediatrics at the University of North Carolina School of Medicine; professor of epidemiology at the UNC Gillings School of Global Public Health; associate chief medical officer for UNC Health Care and medical director of the Department of Infection Prevention for the UNC Medical Center.
NuvaWave is a commercial-grade solution for those who are disinfecting high-touch surfaces. UV Innovators says NuvaWave has undergone rigorous testing with accredited third-party laboratories to gauge its efficacy in killing SARS-CoV-2, the virus that causes COVID-19.
The results from the study completed at Texas Biomedical Research Institute demonstrated that NuvaWave killed more than 99.9% of the live virus in just two seconds, Medendorp said.
NuvaWave was tested at Texas Biomed, an independent nonprofit research institute whose mission is to protect the global community from the threats of infectious diseases through cutting-edge research, said Dr. Cory Hallam, professor and vice president for business development at Texas Biomed.
“For nearly three quarters of a century, the institute has delivered high-quality and reliable scientific data, spanning basic discovery through preclinical development,” Hallam said. “The scientists at Texas Biomed know how to handle the live virus in their biosafety Level 3 lab and to use protocols to safely mimic real-world conditions that helped us document the effectiveness of NuvaWave.”